Ursodeoxycholic acid (UDCA) for the treatment of amoxycillin-clavulanate potassium (Augmentin)-induced intra-hepatic cholestasis: report of two cases.

Abstract

This report describes two patients who developed jaundice within two weeks of receiving an amoxycillin-clavulanate potassium combination. Causes of jaundice, other than drug administration, were excluded. The patients' jaundice and clinical symptoms did not respond to stopping the drug. Ursodeoxycholic acid (750 mg/day) led to a prompt and sustained improvement in their hyperbilirubinaemia and symptoms such as pruritus and fatigue. These cases suggest that ursodeoxycholic acid may be an effective treatment for drug-associated cholestasis.

• Authors: P Katsinelos, T Vasiliadis, P Xiarchos, F Patakiouta, K Christodoulou, I Pilpilidis, N Eugenidis
• Journal: European journal of gastroenterology & hepatology (Eur J Gastroenterol Hepatol) Vol. 12 Issue 3 Pg. 365-8 (Mar 2000) ISSN: 0954-691X [Print] England
• PMID: 10750660 (Publication Type: Case Reports, Journal Article)

Chemical References

• Cholagogues and Choleretics
• Ursodeoxycholic Acid
• Amoxicillin-Potassium Clavulanate Combination

Topics

• Aged
• Aged, 80 and over
• Amoxicillin-Potassium Clavulanate Combination (adverse effects)
• Biopsy
• Cholagogues and Choleretics (therapeutic use)
• Cholestasis, Intrahepatic (chemically induced, drug therapy, pathology)
• Drug Therapy, Combination (adverse effects)
• Humans
• Liver (pathology)
• Male
• Prognosis
• Ursodeoxycholic Acid (therapeutic use)